Novo Nordisk

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FMTX, ECOM, SMBC, COWN

Retrieved on: 
Tuesday, October 4, 2022

If you are a Forma shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Forma shareholder, click here to learn more about your rights and options .
  • If you are a ChannelAdvisor shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Frazier Life Sciences Adds Experienced Biopharmaceutical Executive to Team

Retrieved on: 
Tuesday, October 4, 2022

He is a highly experienced biopharmaceutical executive, and we look forward to working with him to identify and evaluate attractive life sciences investment opportunities.

Key Points: 
  • He is a highly experienced biopharmaceutical executive, and we look forward to working with him to identify and evaluate attractive life sciences investment opportunities.
  • Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals.
  • Since 2005, 62 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As.
  • The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Acquisition – COWN, ECOM, SMBC, FMTX

Retrieved on: 
Tuesday, October 4, 2022

Under the terms of the agreement, ECOM shareholders are expected to receive $23.10 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, ECOM shareholders are expected to receive $23.10 in cash per share they own.
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report.
  • Also, we have recovered or secured a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, AERI, FMTX, CSVI

Retrieved on: 
Monday, October 3, 2022

If you are a Computer Services shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Computer Services shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]sadeh.com .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

Retrieved on: 
Thursday, September 29, 2022

Under the terms of the agreement, Novo Nordisk will make an upfront payment of $70 million in cash to Ventus and provide research and development funding.

Key Points: 
  • Under the terms of the agreement, Novo Nordisk will make an upfront payment of $70 million in cash to Ventus and provide research and development funding.
  • In exchange, Novo Nordisk will receive exclusive worldwide rights to develop and commercialize Ventus lead NLRP3 inhibitor program for a broad range of diseases, including nonalcoholic steatohepatitis (NASH), chronic kidney disease, and other cardiometabolic conditions.
  • In addition, Ventus retains worldwide rights to the companys distinct brain-penetrant NLRP3 inhibitor program.
  • Ventus has developed a highly differentiated NLRP3 inhibitor program with best-in-class properties and compelling pre-clinical results.

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger – COWN, ECOM, SMBC, FMTX

Retrieved on: 
Tuesday, September 27, 2022

Under the terms of the merger, COWN shareholders are expected to receive $39.00 in cash per share they own.

Key Points: 
  • Under the terms of the merger, COWN shareholders are expected to receive $39.00 in cash per share they own.
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report.
  • Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX

Retrieved on: 
Tuesday, September 27, 2022

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO).
  • Under the terms of the proposed transaction, shareholders of Forma will receive $20 in cash for each share of Forma that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

PM360 Magazine Announces Winners of 2022 Trailblazer Awards

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries. In total, 72 winners were named across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022.
  • The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
  • Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry.
  • PM360 will publish profiles of this year's Trailblazer winners in its October issue and on its website.

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Retrieved on: 
Friday, September 23, 2022

Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

Key Points: 
  • Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.
  • It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL).
  • TELLOMAK is a global, open-label, multi-cohort Phase 2 clinical trial recruiting patients with Szary syndrome and mycosis fungoides (MF) in the United States and Europe.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.